Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line ...

Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells’ readiness to attack tumors. Surprisingly, ...

Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically ...

Chimeric antigen receptor, or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell ...

Myocardial infarction research reveals immune-driven cardiac damage. Learn how targeting NK cells could improve heart ...

Background Sympathetic signalling plays a critical role in the initiation and progression of various malignancies. However, ...

Founder Patrick Soon-Shiong highlighted new breast cancer immunotherapy research that supports Anktiva’s scientific rationale. ・A Phase 2 study is already evaluating Anktiva in persistent post-COVID ...

A protein that helps cancer cells hide from the immune system may have a critical weakness, according to research that could ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that new preclinical data for its proprietary SPiKE platform has been accepted ...

A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...

ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...